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time may be more inﬂuential, but more research is needed to
ensure appropriate consideration and valuation of leisure.
PATIENT REPORTED OUTCOMES
PR1
HEALTH RELATED QUALITY OF LIFE IN DIFFERENT STATES
OF BREAST CANCER
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1Karolinska Institutet, Stockholm, Sweden, 2Stockholm School of
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OBJECTIVES: The aim of this study was to describe the health
related quality of life (HRQoL) in different breast cancer disease
states using preference-based measures. METHODS: A total of
361 consecutive breast cancer patients attending the breast
cancer outpatient clinic at Karolinska University hospital Solna
for outpatient visits between April and May 2005 were included
in the study. The EQ-5D self classiﬁer and a direct Time Trade
Off (TTO) question was used to estimate the HRQoL in differ-
ent breast cancer disease states. RESULTS: All of the different
disease states had lower HRQoL compared to the general pop-
ulation. Patients in their ﬁrst year after a primary breast cancer
had a mean EQ-5D index value of 0.696 (95% conﬁdence 
interval (CI): 0.634–0.747)). Patients in their ﬁrst year after a
recurrence had a mean EQ-5D index value of 0.779 (CI:
0.700–0.849). Patients whom had not had a primary breast
cancer diagnosis or a recurrence during the previous year had a
mean EQ-5D index value of 0.779 (CI: 0.745–0.811). Patients
with metastatic disease reported the lowest HRQoL values, and
had a mean EQ-5D index value of 0.685 (CI: 0.620–0.735). The
main driver behind the reduction in HRQoL was pain and dis-
comfort as well as anxiety and depression. TTO values were
higher for all diseases states compared to the EQ-5D index
values. CONCLUSION: This study shows that breast cancer is
associated with a reduction in HRQoL. This effect is most pro-
nounced for patients with metastatic disease. Our results also
indicate that breast cancer has a permanent negative effect on
HRQoL, even if the patient remains recurrence free.
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ESTIMATING UTILITY VALUES FOR HEALTH STATUS USING
THE SPANISH VERSION OF THE SF-36. DATA OF VALIDITY OF
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OBJECTIVES: A new utility index derived of the SF-36, the SF-
6D, was recently developed and has generated an increasing
research in different groups of patients and has also been com-
pared with other utility measures, as it is the EQ-5D. The
purpose of the present work is to validate this index in the
Spanish version of SF-36 with respect to the Spanish version of
the EQ-5D. METHODS: A total of 1843 complete measures of
the SF-36 (version 2) and the EQ-5D (5 items and visual ana-
logic scale-VAS) from 1283 patients who received a solid organ
transplant (kidney, liver, heart or lung) were used. Data were col-
lected at different moments during the ﬁrst year after the surgery
in the context of the Spanish Research Network on Transplan-
tation. SF-6D values were calculated using the model proposed
by its creator. EQ-5D values were calculated using Spanish VAS
tariff (VAS-t) and time-trade off tariff (TTO-t). Spearman corre-
lation coefﬁcients were calculated between SF-6D and EQ-5D
values. RESULTS: Mean value (SD) of SF-6D was 0.67 (0.15)
(range 0.3–1.0), of EQ-5D VAS-t, 0.69 (0.24) (range −0.08–1.0)
and of TTO-t, 0.70 (0.32) (range −0.7–1). Percentage of subjects
scoring the maximum was 1.1% for SF-6D, and 24.5% for the
EQ-5D. SF-6D values had moderate correlation with EQ-5D
VAS-t (r = 0.734) and EQ-5D TTO-t (r = 0.731) (both p < 0.001).
CONCLUSIONS: The SF-6D index derived from the Spanish
version of SF-36 seem to be a valid utility index to be used with
the SF-36 databases from studies made in Spain. However the
moderate correlation between both utility measures indicates
that probably they partially measure different concepts.
PR3
LOW ADHERENCE WITH GASTROPROTECTIVE AGENTS
WHEN CO-PRESCRIBED WITH NSNSAIDS ASSOCIATED WITH
INCREASING RISK OF GI-RELATED HOSPITALISATION
Koncz T, Lister S, Makinson G
Pﬁzer Limited,Tadworth, Surrey, UK
OBJECTIVE: Lack of adherence with gastroprotective agents
(GPAs) when prescribed with non-selective (ns) NSAIDs may
increase risk of hospitalisation for gastrointestinal (GI) condi-
tions. This study assessed the effect of frequent nsNSAID use
with varying levels of GPA use on GI outcomes. METHODS:
Prescription data from a primary care database (DIN-LINK),
representative of the UK population, containing records of over
800,000 patients, was used. Patients with osteoarthritis and/or
rheumatoid arthritis who received nsNSAID therapy and co-
prescribed GPA between September 2003 and August 2005 
were identiﬁed. Adherence (proportion of days covered (%)) at
monthly intervals was deﬁned as days on gastroprotective
therapy within a moving window of three consecutive months
on nsNSAID. Patients were assessed according to their level of
GPA use (0–19, 20–39, 40–59, 60–79, 80–99, 100%). Records
of hospitalisation for GI conditions (also available in the data-
base) at monthly intervals were analysed as a function of GPA
adherence. Odds ratios of GI-related hospitalisation between
cohorts of varying GPA use were calculated. Additional analysis
was performed according to GI risk factors. RESULTS: The data-
base identiﬁed 15,956 patients with an NSAID prescription for
at least 75% of the examined period, and of these, 8890 patients
with a GPA co-prescription with at least 20% use. The rate of
GI-related hospitalisation for the deﬁned period was 2.49% with
full (100%) GPA use. The odds ratio for GI related hospitalisa-
tion of the sub-cohorts vs. that with 100% adherence (95% 
CI), in decreasing order according to adherence, was 1.57
(1.14–2.16), 1.49 (0.95–2.36), 2.85 (1.84–4.43), 3.52
(2.28–5.44), 1.47 (1.19–1.81). The odds of GI-related hospital-
isation were up to 3.5 times higher for NSAID users with poorer
GPA adherence. CONCLUSION: Analysis of observational clin-
ical and prescription data revealed that the lower the GPA use
of frequent NSAID users, the higher the rates of hospitalisation
for GI conditions.
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OBJECTIVE: To elicit single-index preferences from people 
with diabetes for treatment with inhaled insulin compared to
injectable insulin. METHODS: Written descriptions were devel-
oped for ﬁve clinical scenarios in Type 1 and Type 2 diabetes
(T1D and T2D): 1) pre-mixed insulin in T1D; 2) basal-bolus
insulin in T1D; 3) pre-mixed insulin in T2D; 4) oral treatment
in T2D; and 5) oral treatment plus basal insulin in T2D. In each
scenario, adjustment or initiation of insulin treatment was
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required due to poor glycaemic control. Two alternative insulin
regimens were described for each scenario: injectable-only or
inhaled insulin to replace or reduce the number of daily injec-
tions. Only the characteristics of treatment varied; equal efﬁcacy
was assumed. Computer-assisted personal interviews were con-
ducted at six UK locations with people with diabetes aged over
18 years. After demonstration of the inhalation and pen injec-
tion devices, 344 respondents (66% male), 132 (mean age 49
years) with T1D and 212 (mean age 63 years) with T2D, rated
scenarios by time trade-off (TTO) and EQ-5D. RESULTS: A
majority of respondents preferred inhalation variants; the pro-
portions ranging from 63% to 81% across the scenarios, with
generally less than 10% indifferent between variants. Mean dif-
ferences between variants in TTO scores were 0.074, 0.076,
0.088, 0.053 and 0.043 for the 5 scenarios respectively (p <
0.005 for all comparisons). Mean EQ-5D differences between
variants were 0.043, 0.029, 0.037, 0.020, 0.021 for the 5 sce-
narios respectively (p < 0.05 for scenarios 1 and 3), driven mainly
by differences in pain/discomfort. Mean self-rated health was
similar between T1D and T2D respondents, at 0.83 (TTO) and
0.75 (EQ-5D). CONCLUSIONS: Inhaled insulin may offer 
the prospect for improved patient satisfaction when a patient’s
injectable insulin regimen requires adjustment. TTO was more
sensitive than EQ-5D to differences between scenarios and dif-
ferences between treatment variants within scenarios.
SCHIZOPHRENIA
SZ1
EFFECTIVENESS AND COSTS OF ATYPICAL VERSUS TYPICAL
ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA IN
ROUTINE CARE
Stargardt T1, Weinbrenner S1, Busse R1, Juckel G2, Gericke CA3
1Berlin University of Technology, Berlin, Berlin, Germany, 2Ruhr
University School of Medicine, Bochum, Bochum, Germany, 3The
University of Adelaide, Adelaide, South Australia, Australia
OBJECTIVES: To analyse the effectiveness, costs and side-effects
of atypical versus typical antipsychotics for schizophrenia in
routine care. METHODS: A retrospective cohort study using
routine data from a statutory sickness fund in Germany with 5.4
million insured. Patients discharged from hospital with an ICD-
10 diagnosis of schizophrenia in 2003 were followed for 12
months. Rehospitalisation rates, mean hospital days, time to ﬁrst
hospital readmission, cost of inpatient and pharmaceutical care
and prescriptions to treat side-effects during follow-up were
analysed. To control for confounding, a severity index was con-
structed using data on prior hospitalisations due to schizophre-
nia in 2000, 2001 and 2002. RESULTS: A total of 3121 patients
were included into the study. There were no statistically signiﬁ-
cant differences in the effectiveness of atypical versus typical
antipsychotics on rehospitalisation during follow-up (rehospital-
isation rate ratio 1.07, 95% CI 0.86 to 1.33). Patients treated
with atypical antipsychotics received signiﬁcantly less medication
to treat extrapyramidal symptoms than those receiving typical
drugs (relative risk 0.26, 95% CI 0.18 to 0.38). There were con-
sistent but statistically non-signiﬁcant observations of atypical
drugs being more effective for severe cases (>61 prior hospital
days per year), whereas for new cases (no prior hospitalisation
in 2000–2002) and those in the mild and moderate severity strata
(0–14 and 14–61 prior hospital days per year) typical antipsy-
chotics seemed more effective in reducing various rehospitalisa-
tion outcomes. Costs were largely driven by inpatient care.
CONCLUSIONS: The effectiveness of atypical antipsychotics
for schizophrenia on rehospitalisation measures appeared similar
to typical drugs, whereas atypical antipsychotics clearly had a
favourable side-effect proﬁle with less medication against
extrapyramidal symptoms prescribed. Atypical antipsychotics
might be more effective for severe cases, typical drugs for new,
mild and moderate cases. With the exception of severe cases, the
higher costs for atypical antipsychotics were not offset by savings
from reduced inpatient care.
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TREATMENT PERSISTENCE WITH DIFFERENT
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OBJECTIVES: To proﬁle trends in the levels of treatment per-
sistence over time across several typical and atypical antipsy-
chotic agents among patients with schizophrenia in the Veterans
Health Administration (VA). METHODS: Using VA ﬁscal years
2000–2004, we deﬁned initiation of the target agent as 6-month
“clean” period of no target drugs prior to initiation and reserved
one year following the initiation to calculate treatment persis-
tence, or time to discontinuation, as deﬁned by a gap of >15 days
(a sensitivity analysis was also conducted using a gap of >30
days). Using a ﬂoating data approach, we created four time
periods for which analyses were conducted for each period. We
calculated hazard ratio using Cox proportional method and used
a multi-stage regression model, in which one set of covariates
was introduced into the model sequentially. RESULTS: Com-
pared to patients who initiated typical antipsychotics, those who
initiated atypical antipsychotics tended to have better treatment
persistence as reﬂected in longer stay on the medication within
one year between initiation and the ﬁrst gap of >15 or >30 days
(99 vs. 141 days on average; p < 0.001). However, between
October 1, 1999 and March 31, 2005, treatment persistence
with typical antipsychotics remained the same, whereas treat-
ment persistence with atypical antipsychotics decreased from
149 to 135 days. Among individual typical antipsychotics, treat-
ment persistence with chlorpromazine decreased from 110 to102
days, treatment persistence with haloperidol remained the same,
whereas treatment persistence with perphenazine increased from
116 to 128 days. CONCLUSION: Despite being efﬁcacious in
reducing symptoms of schizophrenia, the likelihood of sustain-
ing control of schizophrenia may depend on treatment persis-
tence. However, poor treatment persistence with antipsychotics
is a common problem among patients with schizophrenia. Future
research needs to explore factors associated with different levels
of treatment persistence across different antipsychotics.
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OBJECTIVE: To determine predictors of Global Assessment of
Functioning (GAF) score changes in Australian subjects with
schizophrenia treated with risperidone long-acting injection
(RLAI). METHODS: e-STAR (electronic-Schizophrenia Treat-
ment Adherence Registry) is an ongoing international observa-
